User profiles for J. Lager
 | Joanne J LagerChief Medical Officer, iTeos Therapeutics Verified email at iteostherapeutics.com Cited by 1902 |
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2 …
…, S Zweegman, M Talpaz, J Lager… - The Lancet …, 2017 - thelancet.com
… J-JK reports personal fees and non-financial support from Novartis and Shire, and grants
from AOP Orphan. RVT reports participation in advisory boards and speaker bureaus for Incyte …
from AOP Orphan. RVT reports participation in advisory boards and speaker bureaus for Incyte …
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
…, GM Matthys, B Ma, JP Hodge, JJ Lager - Gynecologic …, 2010 - Elsevier
OBJECTIVE: The progression-free and median survival of patients with advanced ovarian
cancer has not appreciably improved over the last decade. Novel targeted therapies, …
cancer has not appreciably improved over the last decade. Novel targeted therapies, …
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models
…, S Witzel, Q Yu, YA Zhang, G Zheng, J Lager… - Science translational …, 2021 - science.org
Local immunotherapy ideally stimulates immune responses against tumors while avoiding
toxicities associated with systemic administration. Current strategies for tumor-targeted, gene-…
toxicities associated with systemic administration. Current strategies for tumor-targeted, gene-…
[PDF][PDF] Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies
Purpose A phase I study was conducted to determine the maximum-tolerated dose (MTD),
toxicity profile, and pharmacokinetics of a novel purine nucleoside, nelarabine, a soluble …
toxicity profile, and pharmacokinetics of a novel purine nucleoside, nelarabine, a soluble …
Ethnic and gender differences in psychosocial factors, glycemic control, and quality of life among adult type 2 diabetic patients
R Misra, J Lager - Journal of Diabetes and its Complications, 2009 - Elsevier
Objective To examine ethnic and gender differences in psychosocial factors, eg, social
support and acceptance of the disease, knowledge levels, perceived difficulty in adherence …
support and acceptance of the disease, knowledge levels, perceived difficulty in adherence …
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high‐fat or low‐fat meal in patients with advanced solid tumors
…, CJ Sweeney, JP Hodge, JJ Lager… - Clinical …, 2010 - Wiley Online Library
Pazopanib is an oral angiogenesis inhibitor of vascular endothelial growth factor (VEGF)
receptor, platelet‐derived growth factor receptor, and cytokine receptor. This open‐label, …
receptor, platelet‐derived growth factor receptor, and cytokine receptor. This open‐label, …
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified …
…, T Arumugham, Y Xu, CF Xu, J Lager… - Clinical …, 2010 - Wiley Online Library
Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet‐derived
growth factor receptor, and c‐kit kinases, inhibits multiple cytochrome P450 (CYP450) …
growth factor receptor, and c‐kit kinases, inhibits multiple cytochrome P450 (CYP450) …
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade …
Background This phase I study aimed to evaluate safety, maximum tolerated dose,
pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a …
pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a …
Electronic Structure and Luminescence of Quasi-Freestanding MoS2 Nanopatches on Au(111)
Monolayers of transition metal dichalcogenides are interesting materials for optoelectronic
devices due to their direct electronic band gaps in the visible spectral range. Here, we grow …
devices due to their direct electronic band gaps in the visible spectral range. Here, we grow …
[HTML][HTML] Catchbasin technology overview and assessment
JA Lager, WG Smith, G Tchobanoglous - 1977 - books.google.com
… Lager, William G. Smith, and George Tchobanoglous Metcalf & Eddy, Inc., Palo Alto,
California 94303 in association with … Lager, Project Director, and William G. Smith, Project …
California 94303 in association with … Lager, Project Director, and William G. Smith, Project …